The Global IV and Oral Iron Drugs Market accounted for $1.6 billion in 2020 and is estimated to be $3.3 billion by 2030 and is anticipated to register a CAGR of 7.5%. Iron is a vital component for all living organisms as they are essential for the smooth functioning of various metabolic processes that includes oxygen transport, electron transport and DNA synthesis.
Iron is included in the production of erythrocytes (RBCs) that transport oxygen in the blood. The lack of proper levels of iron or decreased total iron contents in the body is called as iron deficiency (ID). Absence of adequate iron levels will decrease the production of RBCs in the body, therefore, affecting the transport of oxygen to different parts of the body. The report “ Global IV and Oral Iron Drugs Market, By Route of Administration (Oral Iron Drugs and IV Iron Drugs), By Application (Nephrology, Obstetrics & Gynecology (OBGYN), Cardiac & Thoracic Surgeries, Surgeries, Gastroenterology, Oncology, and Heart Failure), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Trends, Analysis and Forecast till 2030” Key Highlights:
- In 2018, Shield Therapeutics signed an agreement with Norgine for the product Feraccru. Due to this agreement, Norgine received right for the commercialization for Feraccru from the Shield Therapeutics.
The increase in the population of the iron deficiency leads to highly prevalent nutritional disorders and around 1/4th population is affected globally which is the major driving factor for the growth of the global market. As per the World Health Organization (WHO), effective and timely treatment of ID can raise both national productivity levels by as much as 20% and also rise in restore personal health. Additionally, the increase in demand for non-dextran IV iron therapeutics for the treatment of iron deficiency is the propelling factor for the growth of the target market. To know the upcoming trends and insights prevalent in this market, click the link Key Market Insights
The Global IV and Oral Iron Drugs Market accounted for $1.6 billion in 2020 and is estimated to be $3.3 billion by 2030 and is anticipated to register a CAGR of 7.5%. The global IV and oral iron drugs market is segmented based on the route of administration, application, and region.
- Based on the route of administration, the global IV and oral iron drugs market is segmented into the oral iron drugs and IV iron drugs. IV iron drugs are the dominating drugs for the route of administration segments due to the fast and timely effect of IV iron drugs.
- Based on application, the target market is bifurcated into nephrology, obstetrics & gynaecology (OBGYN), cardiac & thoracic surgeries, surgeries, gastroenterology, oncology, and heart failure.
- Based on the region the global IV and oral iron drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounts highest revenue share to the global IV and oral iron drugs market due to the growing population of iron deficiency and rise in the geriatric population.
Competitive Landscape: The key players operating the global IV and oral iron drugs market involves VIFOR Pharma Group, Daiichi Sankyo Company, Amag Pharmaceuticals, Akebia Therapeutics, Shield Therapeutics, Pharmacosmos, Allergan, Sunny Pharmaceutical, AOP Orphan Pharmaceuticals, and Salveo Lifecare. The market report provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Get Report